Elanco Animal Health Incorporated $ELAN Shares Sold by Skylands Capital LLC

Skylands Capital LLC cut its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 27.6% during the fourth quarter, HoldingsChannel reports. The firm owned 213,600 shares of the company’s stock after selling 81,600 shares during the quarter. Skylands Capital LLC’s holdings in Elanco Animal Health were worth $4,834,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Certuity LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter worth $232,000. Torren Management LLC acquired a new stake in Elanco Animal Health in the fourth quarter valued at $46,000. Mitsubishi UFJ Trust & Banking Corp raised its stake in Elanco Animal Health by 36.5% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 97,803 shares of the company’s stock valued at $2,213,000 after buying an additional 26,129 shares in the last quarter. M&T Bank Corp lifted its holdings in Elanco Animal Health by 25.9% during the 4th quarter. M&T Bank Corp now owns 24,490 shares of the company’s stock worth $554,000 after buying an additional 5,032 shares during the last quarter. Finally, Comerica Bank lifted its holdings in Elanco Animal Health by 9.4% during the 4th quarter. Comerica Bank now owns 304,351 shares of the company’s stock worth $6,887,000 after buying an additional 26,274 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of recent analyst reports. Leerink Partners increased their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Friday, March 27th. JPMorgan Chase & Co. increased their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. Finally, Citigroup started coverage on shares of Elanco Animal Health in a research report on Wednesday, April 15th. They set a “buy” rating and a $30.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $27.90.

Elanco Animal Health Stock Down 3.0%

ELAN opened at $22.08 on Tuesday. Elanco Animal Health Incorporated has a one year low of $9.32 and a one year high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The stock has a market capitalization of $10.98 billion, a P/E ratio of -45.99, a price-to-earnings-growth ratio of 2.90 and a beta of 1.88. The business’s 50-day simple moving average is $24.03 and its 200-day simple moving average is $23.23.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business’s revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts anticipate that Elanco Animal Health Incorporated will post 1.03 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.